Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting - PubMed (original) (raw)
Multicenter Study
doi: 10.1038/sj.leu.2404535. Epub 2007 Feb 8.
E R Panzer-Grümayer, G Cazzaniga, T Flohr, R Sutton, A Schrauder, G Basso, M Schrappe, J M Wijkhuijs, M Konrad, C R Bartram, G Masera, A Biondi, J J M van Dongen
Affiliations
- PMID: 17287857
- DOI: 10.1038/sj.leu.2404535
Multicenter Study
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting
V H J van der Velden et al. Leukemia. 2007 Apr.
Abstract
Minimal residual disease (MRD) diagnostics is used for treatment stratification in childhood acute lymphoblastic leukemia. We aimed to identify and solve potential problems in multicenter MRD studies to achieve and maintain consistent results between the AIEOP/BFM ALL-2000 MRD laboratories. As the dot-blot hybridization method was replaced by the real-time quantitative polymerase chain reaction (RQ-PCR) method during the treatment protocol, special attention was given to the comparison of MRD data obtained by both methods and to the reproducibility of RQ-PCR data. Evaluation of all key steps in molecular MRD diagnostics identified several pitfalls that resulted in discordant MRD results. In particular, guidelines for RQ-PCR data interpretation appeared to be crucial for obtaining concordant MRD results. The experimental variation of the RQ-PCR was generally less than three-fold, but logically became larger at low MRD levels below the reproducible sensitivity of the assay (<10(-4)). Finally, MRD data obtained by dot-blot hybridization were comparable to those obtained by RQ-PCR analysis (r(2)=0.74). In conclusion, MRD diagnostics using RQ-PCR analysis of immunoglobulin/T-cell receptor gene rearrangements is feasible in multicenter studies but requires standardization; particularly strict guidelines for interpretation of RQ-PCR data are required. We further recommend regular quality control for laboratories performing MRD diagnostics in international treatment protocols.
Similar articles
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ; European Study Group on MRD detection in ALL (ESG-MRD-ALL). van der Velden VH, et al. Leukemia. 2007 Apr;21(4):604-11. doi: 10.1038/sj.leu.2404586. Epub 2007 Feb 8. Leukemia. 2007. PMID: 17287850 - MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
van der Velden VH, van Dongen JJ. van der Velden VH, et al. Methods Mol Biol. 2009;538:115-50. doi: 10.1007/978-1-59745-418-6_7. Methods Mol Biol. 2009. PMID: 19277574 - Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. van der Velden VH, et al. Leukemia. 2003 Jun;17(6):1013-34. doi: 10.1038/sj.leu.2402922. Leukemia. 2003. PMID: 12764363 Review. - Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M, van der Velden VH, Björklund E, Wijkhuijs JM, Söderhäll S, Mazur J, Björkholm M, Porwit-MacDonald A. Malec M, et al. Leukemia. 2004 Oct;18(10):1630-6. doi: 10.1038/sj.leu.2403444. Leukemia. 2004. PMID: 15295608 - Detection of minimal residual disease in acute leukemia.
van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. van der Velden VH, et al. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54. J Biol Regul Homeost Agents. 2004. PMID: 15471219 Review.
Cited by
- Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).
Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H. Weber A, et al. Exp Hematol Oncol. 2012 Nov 9;1(1):33. doi: 10.1186/2162-3619-1-33. Exp Hematol Oncol. 2012. PMID: 23210797 Free PMC article. - Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, Nachman JB, Carroll AJ, Heerema NA, Gastier-Foster JM, Willman CL, Dai Y, Winick NJ, Hunger SP, Carroll WL, Larsen E. Borowitz MJ, et al. Blood. 2015 Aug 20;126(8):964-71. doi: 10.1182/blood-2015-03-633685. Epub 2015 Jun 29. Blood. 2015. PMID: 26124497 Free PMC article. Clinical Trial. - Development of personalized tumor biomarkers using massively parallel sequencing.
Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu VE. Leary RJ, et al. Sci Transl Med. 2010 Feb 24;2(20):20ra14. doi: 10.1126/scitranslmed.3000702. Sci Transl Med. 2010. PMID: 20371490 Free PMC article. - Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC, Buracchi C, Laqua A, Nierkens S, Sedek L, Flores-Montero J, Hofmans M, Sobral de Costa E, Nováková M, Mejstrikova E, Barrena S, Kohlscheen S, Szczepanowski M, Kulis J, Oliveira E, Jugooa R, de Jong AX, Szczepanski T, Philippé J, van Dongen JJM, Orfao A, Brüggemann M, Gaipa G, van der Velden VHJ. Verbeek MWC, et al. Br J Haematol. 2022 Apr;197(1):76-81. doi: 10.1111/bjh.17992. Epub 2021 Dec 8. Br J Haematol. 2022. PMID: 34881427 Free PMC article. - Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.
Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Leary RJ, et al. Sci Transl Med. 2012 Nov 28;4(162):162ra154. doi: 10.1126/scitranslmed.3004742. Sci Transl Med. 2012. PMID: 23197571 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials